Larnamin granules for oral use 3g/5 g. №30 sachet


Manufacturer: Ukraine

Treatment of concomitant diseases and complications caused by impaired detoxification of the liver (for example, cirrhosis of the liver) with symptoms of latent or severe hepatic encephalopathy.



Larnamin granules Storage

active substance: L-ornithine-L-aspartate;

1 sachet contains L-ornithine-L-aspartate in terms of 100% substance – 3 g;

Excipients: anhydrous citric acid, orange flavoring, lemon flavoring, sodium saccharin, sodium cyclamate, yellow FCF (E 110), povidone, maltitol (E 965).

Larnamin granules Dosage form

Granules for oral solution.

Main physical and chemical properties: a mixture of granules of different sizes of white and orange colors.

Larnamin granules Pharmacotherapeutic group

Drugs used in liver disease, lipotropic substances. Hepatotropic drugs. Code ATX A05B A.

Larnamin granules Pharmacological properties


In vivo action of L-ornithine-L-aspartate due to amino acids, ornithine and aspartate, is carried out using two key methods of detoxification of ammonia: urea synthesis and glutamine synthesis.

Urea synthesis occurs in peri-portal hepatocytes, where ornithine acts as an activator of two enzymes: ornithine carbamoyltransferase and carbamoylphosphate synthetase, as well as a substrate for urea synthesis.

Glutamine synthesis occurs in peripheral hepatocytes. In particular, under pathological conditions, aspartate and dicarboxylate, including products of ornithine metabolism, are absorbed into cells and used there to bind ammonia in the form of glutamine.

Glutamate is an amino acid that binds ammonia under both physiological and pathological conditions. The resulting amino acid glutamine is not only a non-toxic form for the excretion of ammonia, but also activates intracellular glutamine metabolism.

Under physiological conditions, ornithine and aspartate do not limit the synthesis of urea.

Experimental studies in animals have shown that the property of L-ornithine-L-aspartate to reduce ammonia levels is due to the accelerated synthesis of glutamine. In some clinical trials, this improvement in the branched chain amino acid / aromatic amino acid has been shown.

L-ornithine-L-aspartate is rapidly absorbed and cleaved into ornithine and aspartate. The half-life of both amino acids is short – 0.3-0.4 hours. Part of aspartate is excreted in the urine unchanged.


Not studied.

Clinical characteristics.


Treatment of comorbidities and complications caused by impaired liver detoxification function (eg liver cirrhosis) with symptoms of latent or severe hepatic encephalopathy.


Hypersensitivity to L-ornithine-L-aspartate or to any of the excipients.

Severe renal impairment (chronic or acute renal failure). If creatinine levels are above 3 mg / 100 ml, do not use Larnamine®.

Interaction with other drugs and other types of interactions.

No interaction studies have been performed. No data available.

Features of application

Use during pregnancy or breastfeeding.

There are no data on the use of Larnamine® during pregnancy. Animal studies with L-ornithine-L-aspartate to study its toxic effects on reproductive function have not been performed. Therefore, the use of Larnamine® during pregnancy should be avoided.

However, if treatment with Larnamine® during pregnancy is considered necessary for vital signs, the physician should carefully weigh the potential risk to the fetus / child and the expected benefit to the mother.